Central Serous Chorioretinopathy: Signal to Reduce Corticoid in Renal Transplant Recipients?

Abstract

OBJECTIVE The aim of this work was to report the treatment effectiveness of central serous chorioretinopathy (CSCR) in a renal transplant recipient who received conventional therapy with little effect, and then reducing corticoid successively and with a better outcome later. METHODS We performed a retrospective comparison of best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) of a 57-year-old renal transplant recipient who received conventional therapy and reducing corticoid successively after he was diagnosed as CSCR in the left eye. RESULTS The BCVA of the left eye stayed at 20/200 after 3 months' conventional therapy, but rapidly improved to 20/25 after reducing corticoid by one-half. At the same time, SD-OCT showed much more obvious absorption of retinal liquid in the left eye from reducing corticoid than from conventional therapy. Despite the reducing of corticoid by one-half, the patient did not show any signs of rejection of the renal transplant. CONCLUSIONS CSCR may be a sign in renal transplant recipients for reducing corticoid, and reducing corticoid might be a more reliable and safer treatment for such patients.

DOI: 10.1016/j.transproceed.2015.07.017

Cite this paper

@article{OuYang2015CentralSC, title={Central Serous Chorioretinopathy: Signal to Reduce Corticoid in Renal Transplant Recipients?}, author={P-B Ou-Yang and Xiao-sheng Qi and X M Zhu and X-C Duan}, journal={Transplantation proceedings}, year={2015}, volume={47 7}, pages={2236-8} }